FDA Investigator L Gnnmassimia Massimilla, PharmD

L Gnnmassimia Massimilla, PharmD has conducted inspections on 67 sites in 3 countries as of 14 Sep 2006. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
67
Last Inspection Date:
14 Sep 2006
Investigator Role:
FDA Investigation Participant
Redica ID:
100003517
Countries of Inspections:
United States of America, Canada, Germany
FDA Investigators that have inspected at least one site in common with L Gnnmassimia Massimilla, PharmD:
Alanna L Mussawwir Bias, Alia Legaux, Althea A Williams, Amy Kim, Amy Wyan Mai, Andrea P Scott, Andrew B Paglia, DPM, Anissa M Vargas, Armando A Gonzalez, Arthur S Williams, Jr, Benton M Ketron, Bernardica T Sculac Stern, Charisse K Green, Dave M Deroche, Demitria J Xiradakis, Dorothy W Lee, Eric W Anderson, Evelyn Taha, Fatima Bassa, Felix Maldonado, Geoffrey K Kilili, Gregson A Joseph, Helen B Ricalde, Iram R Hassan, PhD, Irina Gaberman, Jacqueline Mdiaz Albertini, Jacqueline S Warner, James A Liubicich, Jorge C Rios, MD, Joy P Matthias, Karen L Kosar, Kenneth H Williams, Kent C Hermann, Kevin A Gonzalez, Kim M Downing, Kimberley A Ricketts, L'oreal F Walker, Lawton W Lum, Leena Thomas, Lisa Mathew, Mark E Chan, Matthew A Spataro, Michael G Mayfield, Mindy M Chou, Myra K Casey, Neali H Lucas, Nealie C Newberger, Nicole M Bell, Omadevi Somai, Investigator, Paul E Stein, Paul Mouris, Perry T Nichols, Peter Abel, Philip F Istafanos, DMV, MS, Samuel Eskenazi, Samuel T Walker, Satheesh Thomas, Sergio Chavez (NMI), Simone E Pitts, Sony Mathews, Sripal R Mada, PhD, Thomas P Hansen, Uduak M Inokon, Valentino Fiorella, Valerie Jgrecek Trinh, Winston R Alejo, Yvette Mlacour Davis, Yvonne M Santiago

L Gnnmassimia Massimilla, PharmD's Documents

Publish Date Document Type Title
February, 2004 FDA 483 Sandra C. Belmont, M.D. - Form 483, 2004-02-10
November, 2001 FDA 483 Hospital For Special Surgery IRB - Form 483, 2001-11-20
November, 2001 EIR Mark P.Figgie, M.D. - EIR, 2001-11-20
March, 2005 FDA 483 Response Orthometrix, Inc. - Form 483R, 2005-03-08
March, 2001 FDA 483 Scioptic International - Form 483, 2001-03-27
November, 2002 FDA 483 Barr Laboratories Inc. - Form 483, 2002-11-12
February, 2002 FDA 483 AMA Laboratories, Inc. - Form 483, 2002-02-26
February, 2004 EIR Sandra C. Belmont, M.D. - EIR, 2004-02-10
May, 2001 FDA 483 Response James C.-Y Chou, M.D. - Form 483R, 2001-06-05
March, 2005 FDA 483 Orthometrix, Inc. - Form 483, 2005-03-04
May, 2003 FDA 483 Blair Ford, MD - Form 483, 2003-05-05
November, 2001 FDA 483 Response Mark P.Figgie, M.D. - Form 483R, 2002-01-04
March, 2001 EIR Jeffrey W. Moses, MD - EIR, 2001-03-09
November, 2002 EIR Barr Laboratories Inc. - EIR, 2002-11-12
July, 2001 FDA 483 Response American Health Foundation - Form 483R, 2001-08-15
January, 2000 FDA 483 Arizona Heart Institute - Form 483, 2000-01-11
May, 2001 EIR Samin K. Sharma - EIR, 2001-05-18
March, 2001 FDA 483 Lenox Hill Hospital - Form 483, 2001-03-09
October, 2002 FDA 483 Sanofi-Synthelabo Inc. - Form 483, 2002-10-15
November, 2002 FDA 483 Response Barr Laboratories Inc. - Form 483R, 2003-02-26
July, 2001 EIR American Health Foundation - EIR, 2001-07-20
May, 2003 FDA 483 Response Blair Ford, MD - Form 483R, 2003-06-01
May, 2003 EIR Blair Ford, MD - EIR, 2003-05-05
April, 2000 EIR Medtronic Vascular, Inc. - EIR, 2000-04-28
May, 2001 FDA 483 James C.-Y Chou, M.D. - Form 483, 2001-05-02
April, 2000 FDA 483 Medtronic Vascular, Inc. - Form 483, 2000-04-28
May, 2001 FDA 483 Samin K. Sharma - Form 483, 2001-05-18
July, 2001 FDA 483 American Health Foundation - Form 483, 2001-07-20
March, 2005 EIR Orthometrix, Inc. - EIR, 2005-03-04
March, 2001 EIR Scioptic International - EIR, 2001-03-27
May, 2001 EIR James C.-Y Chou, M.D. - EIR, 2001-05-02
April, 2004 FDA 483 Continuum Medical Group at DOCS - Form 483, 2004-04-15

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more